Achillion is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease - HCV and resistant bacterial infections.
The Company's focus is currently on developing three clinical candidates for the treatment of chronic hepatitis C infection. First, Achillion is developing sovaprevir, a proprietary potent, once-daily NS3 protease inhibitor currently in Phase II clinical development. Second, Achillion is evaluating in Phase 1 ACH-2684, a highly potent, pan-genotypic inhibitor of HCV NS3 protease with pico-molar potency. Finally, Achillion is advancing the a second-generation NS5A inhibitor designated ACH-3102, a potent inhibitor of HCV NS5A that demonstrates pico-molar potency, pan-genotypic activity, and an enhanced resistance profile compared to first-generation NS5A inhibitors. Achillion also has a portfolio of antibacterial drug candidates for the treatment of serious, resistant bacterial infections. Each of these programs was discovered through Achillion's own proprietary internal drug discovery efforts.
Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.
Achillion is headquartered in New Haven, Connecticut. Achillion's Common Stock trades on the NASDAQ market under the symbol: ACHN.
